Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran Etexilate Formulations with Pantoprazole
NCT02170896Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2001
- Primary completion
- Dec 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Amount of drug excreted into urine and Area under the concentration time course at steady state at Day 3. Started Oct 2001; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02170896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170896.